Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1995-06-07
1998-12-01
Ford, John M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514 81, 544244, 544257, C07D47502, A61K 31495
Patent
active
058439439
ABSTRACT:
Novel, heterocyclic compounds having at least one ring nitrogen, disclosed side chains and, in some embodiments, an oxygen ortho to the ring nitrogen inhibit inflammatory responses associated with TNF-.alpha. and fibroblast proliferation in vivo and in vitro. The compounds of the invention neither appreciably inhibit the activity of cAMP phosphodiesterase nor the hydrolysis of phosphatidic acid, and are neither cytotoxic nor cytostatic. Preferred compounds of the invention are esters. Methods for the use of the novel compounds to inhibit ceramide-mediated intracellular responses to stimuli in vivo (particularly TNF-.alpha.) are also described. The methods are expected to be of use in reducing inflammatory responses (for example, after angioplasty), in limiting fibrosis (for example, of the liver in cirrhosis), in inhibiting cell senescence, cell apoptosis and UV induced cutaneous immune suppression.
REFERENCES:
patent: 5288721 (1994-02-01), Klein et al.
patent: 5294612 (1994-03-01), Bacon et al.
patent: 5366978 (1994-11-01), Furukawa et al.
Curran et al., Chemical Abstracts, vol. 57 5920 d (1962) at 5921(e).
L.o slashed.mo, et al., TGF-.beta.1 and Cyclic AMP Promote Apoptosis in Resting Human B Lymphocytes.sup.1, The Journal of Immunology, 1995, 154: 1634-1643.
Hannun and Obeid, Ceramide: an intracellular signal for apoptosis, Reviews, Feb. 1995, pp. 73-77.
Rice, et al., Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid, Proc. Natl. Acad. Sci. USA, vol. 91, pp. 3857-3861, Apr. 1994, Medical Sciences.
Dressler, et al., Tumor Necrosis Factor-.varies.Activates the Sphingomelyin Signal Transduction Pathway in a Cell-Free System, Science, vol. 255, Mar. 1992, pp. 1715-1718.
Liu, et al., CD14-Dependent Activation of Protein Kinase C and Mitogen-Activated Protein Kinases (p42 and p44) in Human Monocytes Treated with Bacterial Lipopolysaccharide.sup.1, The Journal of Immunology, 1994, 153:2642.
Mathias, et al., Activation of the Sphingomyelin Signaling Pathway in Intact EL4 Cells and in a Cell-Free System by IL-1.beta., Science, vol. 259, pp. 519-522, Jan. 1991.
Peterson, Theresa, Pentoxifylline Prevents Fibrosis in an Animal Model and Inhibits Platelet-derived Growth Factor-driven Proliferation of Fibroblasts, Hepatology, vol. 17, No. 3, pp. 486-493 1993.
Lozano, et al., Protein Kinase C .zeta. Isoform Is Critical for kB-dependent Promoter Activation by Sphingomyelinase*, The Journal of Biological Chemistry, vol. 269, No. 30. Jul. 29, 1994, pp. 19200-19202.
Schrage, et al., Studies on Condensed Pyrimidine Systems. V. (1) The Pyrimidine Systems, Contribution from the Wellcome Research Laboratories, pp. 207-215.
Nishigaki, et al., New Syntheses of a Petridine, Heterocycles, vol. 15, No. 2, 1981, pp. 757-759.
Carson Dennis A.
Cottam Howard B.
Wasson D. Bruce
Ford John M.
The Regents of the University of California
LandOfFree
Compounds for inhibition of ceramide-mediated signal transductio does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for inhibition of ceramide-mediated signal transductio, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for inhibition of ceramide-mediated signal transductio will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2395813